regular treatment inhaled beta2agonists leads subsensitivity bronchoprotective effects effect dosing frequency subsensitivity known aim study assess dosing regimen formoterol associated lesser degree subsensitivity randomized doubleblind crossover study NUMBER asthmatics treated inhaled steroids mean age NUMBER yrs forced expiratory volume second fev1 NUMBER predicted received NUMBER week treatment formoterol dry powder NUMBER microg twice daily NUMBER NUMBER h formoterol NUMBER microg daily NUMBER h identical placebo adenosine monophosphate amp bronchial challenge performed NUMBER h dose treatment significant loss protection formoterol twice daily dose geometric mean provocative concentration causing NUMBER fall fev1 pc20 NUMBER versus NUMBER mg x loss p0006 formoterol daily NUMBER versus NUMBER mg x loss p0005 compared placebo NUMBER versus NUMBER mg x nonsignificant significant difference degree loss protection formoterol twice daily protection significant difference active treatments placebo dose residual protection active treatments placebo significant patients taking inhaled corticosteroids regular formoterol NUMBER micreog daily induces similar degree subsensitivity adenosine monophosphate bronchial challenge formoterol NUMBER microg twice daily turn suggests dosing interval development tolerance formoterol prolonged occupancy airway long acting daily placebo controlled double dummy ml NUMBER NUMBER fold ml NUMBER NUMBER fold ml NUMBER dose NUMBER h beta2 adrenoceptors